China Resources Double-Crane Pharmaceutical Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on China Resources Double-Crane Pharmaceutical Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how China Resources Double-Crane Pharmaceutical Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with China Resources Double-Crane Pharmaceutical Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
China Resources Double-Crane Pharmaceutical Co Ltd (CR Double-Crane), a subsidiary of China Resources Pharmaceutical Group Ltd, is a pharmaceutical company that provides pharmaceutical products. The company offers products such as prescription medicines, over the counter medicines, consumer health products, and medical devices. It provides its products in the forms of large-volume injections, small-volume injections, powder injections, tablets, hard capsules, soft capsules, ointments, gels, and rinsing solutions, among others. CR Double-Crane is headquartered in Beijing, China.
Headquarters
China
Address
No.1 Lize East Er Road, Wangjing, Chaoyang District, Beijing, 100102
Website
https://www.dcpc.com/
Telephone
86 10 64742227
No of Employees
13,184
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
600062 (SHA)
Revenue (2024)
$1.5B
-1.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
1.2%
(2024 vs 2023)
Market Cap*
$2.5B
Net Profit Margin (2024)
XYZ
3.1%
(2024 vs 2023)
* As of and is in US$
China Resources Double-Crane Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Active pharmaceutical Ingredients |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Plans/Strategy | In July, the company announced its plans to acquire a 23.5% stake in Lier Chemical from Sichuan Jiuyuan Investment Holding Group and Sichuan Huacai Technology. |
| 2026 | Plans/Strategy | In April, the company announced its plans to acquire 100% equity in Nanjing Xinbai Pharmaceutical Co., Ltd from Boya Biological Pharmacy Co. Ltd for RMB235.5 million. |
| 2024 | Plans/Strategy | In February, the company announced its plans to acquire China Resources Zizhu Pharmaceutical from Beijing Pharmaceutical Group. |
Competitor Comparison
| Key Parameters | China Resources Double-Crane Pharmaceutical Co Ltd | Sichuan Kelun Pharmaceutical Co Ltd | Shanghai Shyndec Pharmaceutical Co Ltd | Zhejiang Huahai Pharmaceutical Co Ltd | Kangmei Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Beijing | Chengdu | Shanghai | Taizhou | Shenzhen |
| State/Province | Beijing | Sichuan | Shanghai | Zhejiang | Guangdong |
| No. of Employees | 13,184 | 20,127 | 9,697 | 8,797 | 5,492 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Lu Wenchao | Chairman | Executive Board | 2023 | 50 |
| Zhao Qian | Director; President | Executive Board | 2024 | 46 |
| Huang Wenhao | Chief Financial Officer | Senior Management | 2025 | 43 |
| Man Chao | Vice President | Senior Management | 2021 | 55 |
| Liu Ju | Secretary; Vice President | Senior Management | 2025 | 54 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer